Project Details
Description
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) from Patients with High Allelic Ratio FLT2/ITD
| Status | Finished |
|---|---|
| Effective start/end date | 1/30/13 → 10/1/17 |
Funding
- THE CHILDREN'S HOSPITAL OF PHILADELPHIA
- MILLENIUM PHARM
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.